Monoglyceride/lactate ester permeation enhancer for codelivery of steroids
First Claim
1. A composition of matter for application to a body surface or membrane to coadminister an estrogen and progestogen by permeation through the body surface or membrane, the composition comprising, in combination:
- (a) the estrogen and progestogen to be administered, in a therapeutically effective amount; and
(b) a permeation-enhancing mixture comprising;
(i) 20% by weight of a monoglyceride or a mixture of monoglycerides, and(ii) 12% by weight of a lactate ester or a mixture of lactate esters.
1 Assignment
0 Petitions
Accused Products
Abstract
A composition of matter for application to a body surface or membrane to coadminister an estrogen and progesterone by permeation through the body surface or membrane, the composition comprising, in combination, the estrogen and progesterone to be administered, in a therapeutically effective amount; and a permeation-enhancing mixture comprising a monoglyceride or a mixture of monoglycerides, and a lactate ester or a mixture of lactate esters at specific concentrations. The composition of matter is used to provide hormone replacement therapy to a woman.
-
Citations
31 Claims
-
1. A composition of matter for application to a body surface or membrane to coadminister an estrogen and progestogen by permeation through the body surface or membrane, the composition comprising, in combination:
-
(a) the estrogen and progestogen to be administered, in a therapeutically effective amount; and (b) a permeation-enhancing mixture comprising; (i) 20% by weight of a monoglyceride or a mixture of monoglycerides, and (ii) 12% by weight of a lactate ester or a mixture of lactate esters. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A device for the transdermal coadministration, at a therapeutically effective rate, of an estrogen and progestogen, which device comprises:
-
(a) a reservoir comprising a therapeutically effective amount of an estrogen and progestogen and a skin permeation-enhancing amount of a permeation mixture comprising; (i) 20% by weight of a monoglyceride or a mixture of monoglycerides, and (ii) 12% by weight of a lactate ester or a mixture of lactate esters; (b) a backing on the skin-distal surface of the reservoir; and (c) means for maintaining the reservoir in drug- and permeation enhancing mixture-transmitting relation with the skin. - View Dependent Claims (9, 10, 11, 12, 13, 14, 17, 27)
-
-
8. A device for the transdermal coadministration, at a therapeutically effective rate, of an estrogen and progestogen which device comprises:
-
(a) a first reservoir comprising a therapeutically effective amount of an estrogen and progestogen, and a skin permeation-enhancing amount of a permeation mixture comprising; (i) 20% by weight of a monoglyceride or a mixture of monoglycerides, and (ii) 12% by weight of a lactate ester or a mixture of lactate esters; (b) a second reservoir comprising an excess of the permeation enhancing mixture and the estrogen and progestogen at or below saturation; (c) a rate-controlling membrane between the first reservoir and the second reservoir; (d) a backing on the skin-distal surface of the second reservoir; and (e) means for maintaining the first and second reservoirs in drug- and permeation enhancing mixture-transmitting relation with the skin. - View Dependent Claims (15, 16)
-
-
18. A method for the transdermal coadministration of an estrogen and progestogen, which method comprises:
-
(a) administering the estrogen and progestogen at a therapeutically effective rate to an area of skin; and (b) simultaneously administering a permeation enhancing mixture comprising; (i) 20% by weight based on the drug and permeation enhancer mixture of a monoglyceride or a mixture of monoglycerides, and (ii) 12% by weight based on the drug and permeation enhancer mixture of a lactate ester or a mixture of lactate esters, to the area of skin at a rate which is sufficient to substantially increase the permeability of the area to the drug. - View Dependent Claims (19, 20, 21, 25, 28)
-
-
22. A method for providing hormone replacement therapy to a woman, the method comprising the steps of:
-
(a) administering each component of a drug formulation comprised of an estrogen and progestogen at a therapeutically effective rate to an area of the woman'"'"'s skin; (b) simultaneously administering a skin permeation enhancing amount of a permeation enhancing mixture comprising; (i) 20% by weight of a monoglyceride or a mixture of monoglycerides, and (ii) 12% by weight of a lactate ester or a mixture of lactate esters. - View Dependent Claims (23, 24, 26, 29, 30, 31)
-
Specification